Literature DB >> 15834019

Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation.

C Holmes1, C Ballard, D Lehmann, A David Smith, H Beaumont, I N Day, M Nadeem Khan, S Lovestone, M McCulley, C M Morris, D G Munoz, K O'Brien, C Russ, T Del Ser, D Warden.   

Abstract

OBJECTIVE: To determine whether individuals with Alzheimer's disease (AD) and the K variant allele of butyrylcholinesterase have a slower rate of cognitive decline than those without the K variant allele of butyrylcholinesterase.
METHOD: The cognitive status of 339 community based subjects with AD was assessed with the Mini Mental State Examination at baseline and yearly over a three year follow up period. The rates of cognitive decline of subjects with and without the K variant allele were compared. RESULT: Presence of the K allele was associated with a slower average rate of cognitive decline in subjects with severe AD.
CONCLUSIONS: This finding is consistent with the suggestion that the K variant of butyrylcholinesterase has an important role in disease progression in AD, and this may have implications for treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15834019      PMCID: PMC1739631          DOI: 10.1136/jnnp.2004.039321

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  18 in total

1.  Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications.

Authors:  Clive Holmes; Simon Lovestone
Journal:  Age Ageing       Date:  2003-03       Impact factor: 10.668

2.  Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography.

Authors:  K A Jobst; A D Smith; M Szatmari; A Molyneux; M E Esiri; E King; A Smith; A Jaskowski; B McDonald; N Wald
Journal:  Lancet       Date:  1992-11-14       Impact factor: 79.321

3.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

4.  Apolipoprotein E genotyping by one-stage PCR.

Authors:  P R Wenham; W H Price; G Blandell
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

5.  DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites.

Authors:  C F Bartels; F S Jensen; O Lockridge; A F van der Spek; H M Rubinstein; T Lubrano; B N La Du
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

6.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

7.  Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia.

Authors:  M M Mesulam; C Geula
Journal:  Ann Neurol       Date:  1994-11       Impact factor: 10.422

8.  Factors affecting survival in Alzheimer's disease.

Authors:  A Burns; G Lewis; R Jacoby; R Levy
Journal:  Psychol Med       Date:  1991-05       Impact factor: 7.723

9.  Changes in brain cholinesterases in senile dementia of Alzheimer type.

Authors:  E K Perry; R H Perry; G Blessed; B E Tomlinson
Journal:  Neuropathol Appl Neurobiol       Date:  1978 Jul-Aug       Impact factor: 8.090

10.  Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies.

Authors:  Elaine Perry; Ian McKeith; Clive Ballard
Journal:  Neurology       Date:  2003-06-10       Impact factor: 9.910

View more
  17 in total

1.  Rapid cognitive decline in Alzheimer's disease. Consensus paper.

Authors:  M E Soto; S Andrieu; C Arbus; M Ceccaldi; P Couratier; T Dantoine; J-F Dartigues; S Gillette-Guyonnet; F Nourhashemi; P-J Ousset; M Poncet; F Portet; J Touchon; B Vellas
Journal:  J Nutr Health Aging       Date:  2008-12       Impact factor: 4.075

Review 2.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

3.  Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent.

Authors:  Nigel H Greig; Tadanobu Utsuki; Donald K Ingram; Yue Wang; Giancarlo Pepeu; Carla Scali; Qian-Sheng Yu; Jacek Mamczarz; Harold W Holloway; Tony Giordano; DeMao Chen; Katsutoshi Furukawa; Kumar Sambamurti; Arnold Brossi; Debomoy K Lahiri
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-07       Impact factor: 11.205

4.  An examination of Bayesian statistical approaches to modeling change in cognitive decline in an Alzheimer's disease population.

Authors:  Al Bartolucci; Sejong Bae; Karan Singh; H Randall Griffith
Journal:  Math Comput Simul       Date:  2009-11       Impact factor: 2.463

5.  BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia.

Authors:  Alessandra Bizzarro; V Guglielmi; R Lomastro; A Valenza; A Lauria; C Marra; M C Silveri; F D Tiziano; C Brahe; C Masullo
Journal:  J Neural Transm (Vienna)       Date:  2010-03       Impact factor: 3.575

6.  Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis.

Authors:  Mohammad A Kamal; Xianqin Qu; Qian-Sheng Yu; David Tweedie; Harold W Holloway; Yazhou Li; Yi Tan; Nigel H Greig
Journal:  J Neural Transm (Vienna)       Date:  2008-01-31       Impact factor: 3.575

7.  A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.

Authors:  Agneta Nordberg; Clive Ballard; Roger Bullock; Taher Darreh-Shori; Monique Somogyi
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-07

8.  It all starts at the ends: multifaceted involvement of C- and N-terminally modified cholinesterases in Alzheimer's disease.

Authors:  Amit Berson; Hermona Soreq
Journal:  Rambam Maimonides Med J       Date:  2010-10-31

9.  The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology.

Authors:  Erez Podoly; Deborah E Shalev; Shani Shenhar-Tsarfaty; Estelle R Bennett; Einor Ben Assayag; Harvey Wilgus; Oded Livnah; Hermona Soreq
Journal:  J Biol Chem       Date:  2009-04-21       Impact factor: 5.157

10.  Caffeine inhibits acetylcholinesterase, but not butyrylcholinesterase.

Authors:  Miroslav Pohanka; Petr Dobes
Journal:  Int J Mol Sci       Date:  2013-05-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.